Elevation Point Wealth Partners LLC significantly boosted its investment in Merck & Co., Inc.(MRK) during the first quarter of 2026, increasing its holdings by 108.9% to 116,727 shares.This acquisition, valued at $14.099 million, follows a surge in institutional investor activity, including Chesapeake Wealth Management, South Plains Financial Inc., and Syverson Strege & Co., which all expanded their positions in the pharmaceutical giant.Merck's stock performance in the quarter showed resilience, with a 4.9% year-over-year revenue increase and a net margin of 13.59%.The company recently announced a quarterly dividend of $0.85, yielding 2.6%, and received positive analyst upgrades, including a $155 price target from Scotiabank and a $141 target from Bank of America.Institutional investors now hold 76.07% of Merck's shares, reflecting strong confidence in the company's financial health and growth prospects.

The article also highlights Merck's diversified portfolio, including key products like Keytruda and Gardasil, and its global presence in biopharmaceuticals and animal health.These developments underscore Merck's strategic importance in the healthcare sector and its appeal to institutional investors.